TY - JOUR
T1 - Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer
AU - Kamphues, Carsten
AU - Wittschieber, Daniel
AU - Klauschen, Frederick
AU - Kasajima, Atsuko
AU - Dietel, Manfred
AU - Schmidt, Sven Christian
AU - Glanemann, Matthias
AU - Bahra, Marcus
AU - Neuhaus, Peter
AU - Weichert, Wilko
AU - Stenzinger, Albrecht
PY - 2012/1
Y1 - 2012/1
N2 - Objective: According to recent research, prolyl hydroxylase domain 2 protein (PHD2) plays an important role in human carcinogenesis by inducing neovascularization and tumor growth. The aim of this study was to evaluate PHD2 expression patterns in primary gastric adenocarcinoma and to test for a potential predictive value of PHD2 expression in gastric cancer patients. Methods: In a total of 121 patients, PHD2 expression was investigated by immunohistochemistry in paraffin-embedded tissue and correlated with clinicopathological parameters and patient survival. Results: 64 of 121 gastric carcinomas (52.9%) showed PHD2 expression in tumor cell cytoplasm. In univariate analysis, PHD2-negative patients had a significantly shortened survival in comparison with PHD2-postive patients (19.5 vs. 32.7 months, p = 0.02). Independent prognostic significance could be shown in multivariate analysis for PHD2 expression (p = 0.005), age at diagnosis (p = 0.012), lymph node status (p = 0.016) and R status (p = 0.026). Conclusion: Cytoplasmic PHD2 expression has a strong impact on survival in gastric cancer patients. Therefore, PHD2 represents a useful predictive biomarker in the evaluation of high-risk patients. Furthermore, these results underline the importance of PHD2 in gastric carcinogenesis and may identify PHD2 as a putative target for future gastric cancer therapy.
AB - Objective: According to recent research, prolyl hydroxylase domain 2 protein (PHD2) plays an important role in human carcinogenesis by inducing neovascularization and tumor growth. The aim of this study was to evaluate PHD2 expression patterns in primary gastric adenocarcinoma and to test for a potential predictive value of PHD2 expression in gastric cancer patients. Methods: In a total of 121 patients, PHD2 expression was investigated by immunohistochemistry in paraffin-embedded tissue and correlated with clinicopathological parameters and patient survival. Results: 64 of 121 gastric carcinomas (52.9%) showed PHD2 expression in tumor cell cytoplasm. In univariate analysis, PHD2-negative patients had a significantly shortened survival in comparison with PHD2-postive patients (19.5 vs. 32.7 months, p = 0.02). Independent prognostic significance could be shown in multivariate analysis for PHD2 expression (p = 0.005), age at diagnosis (p = 0.012), lymph node status (p = 0.016) and R status (p = 0.026). Conclusion: Cytoplasmic PHD2 expression has a strong impact on survival in gastric cancer patients. Therefore, PHD2 represents a useful predictive biomarker in the evaluation of high-risk patients. Furthermore, these results underline the importance of PHD2 in gastric carcinogenesis and may identify PHD2 as a putative target for future gastric cancer therapy.
KW - Angiogenesis
KW - EGL nine homolog 1
KW - Gastric cancer
KW - Hypoxia-inducible factor
KW - Prolyl hydroxylase domain 2 protein
UR - http://www.scopus.com/inward/record.url?scp=84855882979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855882979&partnerID=8YFLogxK
U2 - 10.1159/000330170
DO - 10.1159/000330170
M3 - Article
C2 - 22236543
AN - SCOPUS:84855882979
VL - 79
SP - 11
EP - 17
JO - Pathobiology
JF - Pathobiology
SN - 1015-2008
IS - 1
ER -
